BR0316746A - Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550) - Google Patents

Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550)

Info

Publication number
BR0316746A
BR0316746A BR0316746-1A BR0316746A BR0316746A BR 0316746 A BR0316746 A BR 0316746A BR 0316746 A BR0316746 A BR 0316746A BR 0316746 A BR0316746 A BR 0316746A
Authority
BR
Brazil
Prior art keywords
ferm
lineage
streptomyces
macrolide compound
mortierella
Prior art date
Application number
BR0316746-1A
Other languages
English (en)
Inventor
Akifumi Okuda
Satoshi Yamamoto
Takashi Sakai
Susumu Takeda
Takashi Nakashima
Katsura Kanebo
Tomohiro Sameshima
Taira Kato
Naoto Kawamura
Original Assignee
Mercian Corp
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mercian Corp, Eisai Co Ltd filed Critical Mercian Corp
Publication of BR0316746A publication Critical patent/BR0316746A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"MéTODO DE PRODUçãO DO COMPOSTO MACROLIDA 11107D, LINHAGEM STREPTOMYCES SP. AB-1704 (FERM BP-8551), LINHAGEM MORTIERELLA SP. F-1529 (FERM BP-8547) OU LINHAGEM F-1530 (FERM BP-8548), E LINHAGEM AB-1896 (FERM BP-8550)". A presente invenção proporciona um método de produzir o composto macrolida de anel constituído de 12 componentes 11107D que possui uma atividade antitumor mediante transformação biológica. O material de partida que é o composto macrolida de anel constituído de 12 componentes 11107B representado pela fórmula (I) é incubado em presença de uma linhagem pertencente ao gênero Mortierella, ao gênero Streptomyces ou à família Micromonosporaceae (por exemplo, linhagem Streptomyces sp. AB-1704 (FERM BP-8551)), cada um dos quais tema capacidade de transformar o composto macrolida de anel constituído de 12 componentes 11107B em uma substância 11107D representada pela fórmula (II), ou uma preparação de seus micélios cultivados e oxigênio e em seguida a substância 11107D que é um material alvo é coletado a partir da solução de tratamento.
BR0316746-1A 2002-11-29 2003-11-27 Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550) BR0316746A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002346796 2002-11-29
PCT/JP2003/015170 WO2004050890A1 (ja) 2002-11-29 2003-11-27 マクロライド系化合物の製造方法

Publications (1)

Publication Number Publication Date
BR0316746A true BR0316746A (pt) 2005-10-18

Family

ID=32462862

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316746-1A BR0316746A (pt) 2002-11-29 2003-11-27 Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550)

Country Status (13)

Country Link
US (1) US7745198B2 (pt)
EP (1) EP1580278A4 (pt)
JP (1) JP4439401B2 (pt)
KR (1) KR20050086873A (pt)
CN (1) CN1717493A (pt)
AU (1) AU2003284469B2 (pt)
BR (1) BR0316746A (pt)
CA (1) CA2507641A1 (pt)
MX (1) MXPA05005672A (pt)
NO (1) NO20052568L (pt)
NZ (1) NZ540103A (pt)
RU (1) RU2330069C2 (pt)
WO (1) WO2004050890A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI334866B (en) * 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
CA2546614A1 (en) 2003-11-27 2005-06-09 Mercian Corporation Dna participating in hydroxylation of macrolide compound
EP1770165B1 (en) * 2004-07-20 2011-12-21 Eisai R&D Management Co., Ltd. Dna coding for polypeptide participating in biosynthesis of pladienolide
TW200716744A (en) * 2005-05-26 2007-05-01 Eisai R&D Man Co Ltd Genetically modified microorganism and process for production of macrolide compound using the microorganism
WO2007043621A1 (ja) * 2005-10-13 2007-04-19 Eisai R & D Management Co., Ltd. プラジエノライド ｂ及びプラジエノライド ｄの全合成方法
JPWO2008020584A1 (ja) * 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
EP2116542A4 (en) * 2007-01-29 2011-05-04 Eisai R&D Man Co Ltd SOLID OF A MAKROLIDE COMPOUND, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
EP2988597B1 (en) 2013-04-04 2022-06-08 President and Fellows of Harvard College Macrolides and methods of their preparation and use
KR102146726B1 (ko) 2014-05-15 2020-08-21 에자이 알앤드디 매니지먼트 가부시키가이샤 플라디에놀리드 피리딘 화합물 및 사용 방법
JP2017531663A (ja) 2014-10-08 2017-10-26 プレジデント アンド フェローズ オブ ハーバード カレッジ １４員ケトライドならびにそれらの調製および使用の方法
EP3273969A4 (en) 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides with modified desosamine sugars and uses thereof
ES2887201T3 (es) 2015-09-01 2021-12-22 Eisai R&D Man Co Ltd Variantes de empalme asociadas con mutantes neomórficos de SF3B1
WO2017087667A1 (en) 2015-11-18 2017-05-26 Eisai R&D Management Co., Ltd. A solid state form of pladienolide pyridine compounds and methods of use
AU2018235940A1 (en) 2017-03-15 2019-10-17 Eisai R&D Management Co., Ltd. Spliceosome mutations and uses thereof
US11524009B2 (en) 2017-10-31 2022-12-13 Eisai R&D Management Co., Ltd. Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use
MX2020010606A (es) 2018-04-09 2021-01-15 Eisai R&D Man Co Ltd Compuestos de pladienolida y su uso.
AU2019252432B2 (en) 2018-04-12 2023-04-13 Eisai R&D Management Co., Ltd. Pladienolide derivatives as spliceosome targeting agents for treating cancer
AU2019279012A1 (en) 2018-06-01 2020-12-24 Eisai R&D Management Co., Ltd. Methods of using splicing modulators
JP2023553588A (ja) 2020-11-04 2023-12-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 骨髄異形成症候群（ｍｄｓ）のバイオマーカー及びその使用方法
CN114478257A (zh) * 2021-12-29 2022-05-13 福建省山河药业有限公司 一种抗肿瘤霉菌酸类化合物及其制备方法、应用
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04352783A (ja) * 1991-05-27 1992-12-07 Taisho Pharmaceut Co Ltd １２員環マクロライド系化合物
EP1192147A1 (en) 1999-06-03 2002-04-03 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Mycolactone and related compounds, compositions and methods of use
WO2002012533A2 (en) 2000-08-03 2002-02-14 Kosan Biosciences, Inc. Fermentation and purification of mycolactones
TWI312681B (en) * 2001-02-01 2009-08-01 Novel physiologically active substance
TWI233361B (en) 2001-04-13 2005-06-01 Gen Hospital Corp Methods of preventing UVB-induced skin damage
TWI334866B (en) * 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
CA2494536C (en) * 2002-07-31 2011-10-04 Mercian Corporation A 12-membered ring macrolide active substance
WO2007043621A1 (ja) 2005-10-13 2007-04-19 Eisai R & D Management Co., Ltd. プラジエノライド ｂ及びプラジエノライド ｄの全合成方法

Also Published As

Publication number Publication date
CN1717493A (zh) 2006-01-04
US20060141589A1 (en) 2006-06-29
RU2005120390A (ru) 2006-01-27
NO20052568D0 (no) 2005-05-27
WO2004050890A1 (ja) 2004-06-17
AU2003284469A1 (en) 2004-06-23
NZ540103A (en) 2007-05-31
JPWO2004050890A1 (ja) 2006-03-30
NO20052568L (no) 2005-06-29
RU2330069C2 (ru) 2008-07-27
AU2003284469B2 (en) 2008-02-21
EP1580278A4 (en) 2010-08-25
MXPA05005672A (es) 2005-08-16
EP1580278A1 (en) 2005-09-28
US7745198B2 (en) 2010-06-29
JP4439401B2 (ja) 2010-03-24
KR20050086873A (ko) 2005-08-30
CA2507641A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
BR0316746A (pt) Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550)
Hegazy et al. Microbial biotransformation as a tool for drug development based on natural products from mevalonic acid pathway: A review
Vu et al. Antimicrobial and cytotoxic properties of bioactive metabolites produced by Streptomyces cavourensis YBQ59 isolated from Cinnamomum cassia Prels in Yen Bai Province of Vietnam
Hur et al. Isolation of an anaerobic intestinal bacterium capable of cleaving the C-ring of the isoflavonoid daidzein
Zhou et al. New azaphilones and tremulane sesquiterpene from endophytic Nigrospora oryzae cocultured with Irpex lacteus
Jiang et al. Conversion of puerarin into its 7-O-glycoside derivatives by Microbacterium oxydans (CGMCC 1788) to improve its water solubility and pharmacokinetic properties
Indananda et al. Linfuranone A, a new polyketide from plant-derived Microbispora sp. GMKU 363
Amin et al. Comparative studies of acidic and enzymatic hydrolysis for production of soyasapogenols from soybean saponin
Hu et al. A novel antimicrobial epoxide isolated from larval Galleria mellonella infected by the nematode symbiont, Photorhabdus luminescens (Enterobacteriaceae)
Hara et al. Dehydropropylpantothenamide isolated by a co-culture of Nocardia tenerifensis IFM 10554 T in the presence of animal cells
Dong et al. Production of a new tetracyclic triterpene sulfate metabolite sambacide by solid-state cultivated Fusarium sambucinum B10. 2 using potato as substrate
Xie et al. Methylglucosylation of phenolic compounds by fungal glycosyltransferase-methyltransferase functional modules
Maatooq et al. Bioactive microbial metabolites from glycyrrhetinic acid
Niitsuma et al. Sinefungin VA and dehydrosinefungin V, new antitrypanosomal antibiotics produced by Streptomyces sp. K05-0178
Wu et al. A new 2 H-benzindazole compound from Alternaria alternata Shm-1, an endophytic fungus isolated from the fresh wild fruit of Phellinus igniarius
Maatooq et al. Metabolism of daidzein by Nocardia species NRRL 5646 and Mortierella isabellina ATCC 38063
Qin et al. Secondary metabolites of the zoanthid-derived fungus Trichoderma sp. TA26-28 collected from the south China sea
Lang et al. Improved production of bioactive glucosylmannosyl-glycerolipid by sponge-associated Microbacterium species
Xie et al. Micromonospora mangrovi sp. nov., isolated from mangrove soil
JP5283927B2 (ja) 新規化合物アミコラマイシン、その製造方法及びその用途
US6046041A (en) Method for producing marine-derived compounds and novel compounds produced therefrom
US4759928A (en) Antibiotic: Treponemycin
WO2010122669A1 (ja) 新規化合物アミコラマイシン、その製造方法及びその用途
Lv et al. Polyketides with potential bioactivities from the mangrove-derived fungus Talaromyces sp. WHUF0362
Yang et al. Endophytic Microbes from Medicinal Plants in Fenghuang Mountain as a Source of Antibiotics

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCIAN CORPORATION (JP) , EISAI R AND D MANAGEMEN

Free format text: TRANSFERIDO DE: EISAI CO., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.